C75: A NEW WAY TO ACT ON CANCER CELL DIVISION

Features

In contrast to normal cells, most tumor cells contain multiple centrosomes. They can divide successfully because they can cluster these centrosomes into 2 spindle poles. To tackle this feature, C75 (a small molecule derived from thienoisoquinoline) targets the centrosome clustering by disrupting the integrity of the mitotic pole. C75 could be used alone or in combination therapy with other anti-cancer agents. With C75, cancer cell viability can be selectively reduced. The potential treatment for multiple cancer types including colorectal, lung cancer and breast cancers.

Benefits

  • C75 is a small molecule

  • C75 is easy to produce

  • C75 is non-toxic

  • C75 can reduce cancer cell viability

Current Status

Pre-clinical development stage: invitro proof of concept completed in colorectal and lung cancer models 

Opportunities

Market opportunities:

  • Lung cancer and colorectal cancer are the two biggest killer cancers
  • Lung cancer has the lowest 5-years survival rate (1.7/10)
  • Lung cancer and colorectal cancer have the two highest global cancer therapeutics market share in 2017 (lung=13% and colorectal=9.7%)

Patents opportunities: PCT/CA2017/051473 & PCT/CA2017/051454

Business opportunities: partnering/pre-clinical development/in-licensing

ecommALIGO C75